Millipore Sigma Vibrant Logo

539225 Protein Disulfide Isomerase Inhibitor III, PACMA 31 - Calbiochem

Protein Disulfide Isomerase Inhibitor III, PACMA 31 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: PDI Inhibitor III, Ethyl 2-(2-(N-(2,4-dimethoxyphenyl)propiolamido)-2-(thiophen-2-yl)acetamido)acetate

539225
価格＆在庫状況を照会

概要

Replacement Information

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
539225-25MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 ｶﾞﾗｽﾋﾞﾝ 25 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA cell-permeable propynoic acid carbamoyl methyl amide (PACMA) that is more potent than PAO (Cat. No. 521000) in inhibiting PDI (protein disulfide isomerase) thioloxidoreductase activity (IC50 = 10 and 85 µM, respectively; 1h preincubation) by altering PDI secondary conformation via covalent modification of active site C(397)GHC(400) motif cysteines. Shown to inhibit the proliferation of human ovarian cancer cells in vitro (GI50 (72 h) = 0.32, 0.9, and 1.4 µM in OVCAR-3, OVCAR-8, and NCI/ADR-RES cultures, respectively), and suppress OVCAR-8 tumor growth in mice in vivo via either i.p. (100 mg/kg/5d/wk or 40 mg/kg/d) or p.o. (20 mg/kg/d to 200 mg/kg/d with 20 mg increment every 3 days; then 200 mg/kg/d til day 62). The commonly used PDI inhibitor Bacitracin (Cat. No. 1951) on the other hand is not suitable for in vivo studies due to its nephrotoxicity and low membrane permeability.
      Catalogue Number539225
      Brand Family Calbiochem®
      SynonymsPDI Inhibitor III, Ethyl 2-(2-(N-(2,4-dimethoxyphenyl)propiolamido)-2-(thiophen-2-yl)acetamido)acetate
      References
      ReferencesXu, S., et al. 2012. Proc. Natl. Acad. Sci. USA 109, 16348.
      Product Information
      FormLight beige solid
      Hill FormulaC₂₁H₂₂N₂O₆S
      Chemical formulaC₂₁H₂₂N₂O₆S
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetPDI
      Primary Target IC<sub>50</sub>10 µ
      Purity≥99% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      539225-25MGCN 04055977268966

      Documentation

      参考資料

      参考資料の概要
      Xu, S., et al. 2012. Proc. Natl. Acad. Sci. USA 109, 16348.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-July-2013 JSW
      SynonymsPDI Inhibitor III, Ethyl 2-(2-(N-(2,4-dimethoxyphenyl)propiolamido)-2-(thiophen-2-yl)acetamido)acetate
      DescriptionA cell-permeable propynoic acid carbamoyl methyl amide (PACMA) that is more potent than PAO (Cat. No. 521000) in inhibiting PDI (protein disulfide isomerase) thioloxidoreductase activity (IC50 = 10 and 85 µM, respectively, in insulin aggregation assays; 1h preincubation) by altering PDI secondary conformation via covalent modification of either of the two cysteine residues within the active site C(397)GHC(400) motif. Shown to inhibit the proliferation of human ovarian cancer cells in vitro, including OVCAR-3, OVCAR-8, and the doxorubicin- (Cat. No. 324380) and paclitaxel- (Cat. No. 580555 & 580556) resistant NCI/ADR-RES (GI50 (72 h) = 0.32, 0.9, and 1.4 µM, respectively), and suppress OVCAR-8-derived tumor growth in mice in vivo via either i.p. (by 85%; 100 mg/kg/5d/wk for 3 wks, 40 mg/kg/d for 7 days, then no treatment til day 62) or p.o. (by 65%; 20 mg/kg/d to 200 mg/kg/d with 20 mg increment every three days; then 200 mg/kg/d til day 62). The commonly used PDI inhibitor Bacitracin (Cat. No. 1951) on the other hand is not suitable for in vivo studies due to its nephrotoxicity and low membrane permeability.
      FormLight beige solid
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₂₁H₂₂N₂O₆S
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (100 mg/ml). Use only fresh DMSO for reconstitution.
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesXu, S., et al. 2012. Proc. Natl. Acad. Sci. USA 109, 16348.